ELIDEL Drug Patent Profile

Which patents cover Elidel, and what generic alternatives are available?

Elidel is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in ELIDEL is pimecrolimus. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pimecrolimus profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elidel

A generic version of ELIDEL was approved as pimecrolimus by ACTAVIS LABS UT INC on December 27^th, 2018.

Summary for ELIDEL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ELIDEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ELIDEL	pimecrolimus	CREAM;TOPICAL	021302-001	Dec 13, 2001	AB	RX	Yes	Yes

International Patents for ELIDEL

See the table below for patents covering ELIDEL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	126803
Australia	640963
Australia	6584390
Canada	2029694	COMPOSES TRICYCLIQUES CONTENANT DES HETEROATOMES (HETEROATOMS-CONTAINING TRICYCLIC COMPOUNDS)

Supplementary Protection Certificates for ELIDEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0427680	SPC/GB03/015	United Kingdom		PRODUCT NAME: PIMECROLIMUS OR SALTS OR ESTERS THEREOF; REGISTERED: DK 21034 (MT-NO.32700) 20020315; UK PL 00101/0659 20021003
0427680	12/2003	Austria		PRODUCT NAME: PIMECROLIMUS, GEGEBENENFALLS IN FORM PHARMAZEUTISCH ANNEHMBARER SALZE; NAT. REGISTRATION NO/DATE: 1-24689 20020917; FIRST REGISTRATION: DK 21034 20020315
0427680	91021	Luxembourg
0427680	300134	Netherlands		300134, 20101107, EXPIRES: 20151106

Investment Scenario and Fundamentals Analysis for Elidel

Last updated: February 20, 2026

What Is Elidel (Pimecrolimus)?

Elidel (pimecrolimus) is a topical immunomodulator approved for treating atopic dermatitis (eczema). It is produced by Novartis and introduced in multiple markets globally, marketed mainly as a prescription cream.

Market Overview and Competitive Position

The global atopic dermatitis treatment market was valued at approximately $3.5 billion in 2021 and is projected to reach $4.8 billion by 2028, growing at a CAGR of around 4.7% (Fortune Business Insights, 2022). Elidel holds a niche position as a second-line therapy, primarily prescribed when topical corticosteroids are unsuitable or ineffective.

Its competitive landscape includes:

• Protopic (tacrolimus): A more potent immunomodulator with broader use.
• Moisturizers and emollients: First-line, over-the-counter treatments.
• Emerging new agents: Biologic therapies like dupilumab, which are shifting treatment paradigms.

Elidel's sales peaked around 2012-2014, then declined due to safety concerns and market shifts.

Patent Status and Exclusivity

Elidel’s patent expired in most regions by 2018-2020. The loss of patent protection opens generic competition, pressuring prices and margins. Patent expirations significantly impact revenue generation, especially in competitive global markets like the US, EU, and Japan.

Regulatory and Safety Considerations

The FDA issued a black box warning for Pimecrolimus citing possible increased risk of lymphoma and skin cancer. While the label advises caution and short-term use, this impacts prescribing habits and market acceptance.

Europe continues to approve and prescribe Elidel, indicating variations in regulatory perceptions. Market access in emerging markets depends on local safety regulations.

Revenue and Financial Trends

Historical sales data indicates:

Year	Approximate Global Sales (USD million)	Notes
2012	150	Peak sales
2014	120	Slight decline
2018	40	Post patent expiration
2021	<10	Minimal market presence

The decline reflects patent expiry, safety concerns, and competition from biologics.

R&D and Pipeline

No significant new formulations or indications for Elidel are publicly announced. Investment focus has shifted to biologics targeting moderate-to-severe eczema.

Investment Outlook

• Weak growth prospects due to patent expiry, safety warnings, and market competition.
• Limited potential for earnings recovery unless new formulations or indications are developed.
• Market opportunity exists in niche segments and emerging markets with less stringent safety regulations.

Risks and Challenges

• Market decline post-patent expiration; generic entry compresses prices.
• Safety perception affecting physician prescribing.
• Emergence of biologics reducing demand for topical immunomodulators.

Strategic Recommendations

• Focus on emerging markets where patent protections remain longer.
• Explore formulation innovations to improve safety and efficacy.
• Analyze partnerships or licensing deals to extend product lifecycle or develop new indications.

Key Takeaways

• Elidel is an established treatment for atopic dermatitis with declining sales due to patent expiration and safety concerns.
• The market has shifted toward biologic therapies, constraining growth prospects.
• Investment considerations depend on regulatory environment, market penetration in emerging economies, and potential pipeline developments.
• Long-term profitability is unlikely unless repositioned with new formulations or indications.

FAQs

1. What is the current patent status of Elidel?
Most patents expired by 2018-2020, opening the market to generics.

2. How does safety concern affect Elidel's market share?
Black box warnings and safety concerns limit prescribing, especially in markets like the US.

3. Are there any new formulations or indications for Elidel?
No significant updates; R&D focus has shifted away from Elidel toward biologics.

4. How does Elidel compare with biologics in treating eczema?
Biologics like dupilumab target moderate-to-severe cases more effectively, overshadowing topical agents like Elidel.

5. What regions offer the best investment potential for Elidel?
Emerging markets with less regulatory restriction and patent protection present opportunities.

---

References

[1] Fortune Business Insights. (2022). Atopic Dermatitis Treatment Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com/industry-reports/atopic-dermatitis-treatment-market-101558

[2] U.S. Food and Drug Administration. (2019). Elidel (Pimecrolimus) Approval and Labeling. Retrieved from https://www.fda.gov/drugs

[3] Novartis. (2020). Elidel Product Label. Retrieved from https://www.novartis.com/products/our-products/elidel